GOLDMAN SACHS GROUP INC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 78 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$790,297
-62.1%
537,617
-18.0%
0.00%
Q2 2023$2,086,153
+59.1%
656,023
+18.1%
0.00%
Q1 2023$1,311,051
-68.8%
555,530
-54.2%
0.00%
-100.0%
Q4 2022$4,207,631
+49.0%
1,212,574
+214.8%
0.00%0.0%
Q3 2022$2,824,000
+115.1%
385,220
+91.3%
0.00%
Q2 2022$1,313,000
+39.5%
201,407
+8.1%
0.00%
Q1 2022$941,000
+16.7%
186,356
+79.0%
0.00%
Q4 2021$806,000
-75.4%
104,112
-48.5%
0.00%
-100.0%
Q2 2021$3,281,000202,0340.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q4 2021
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$69,963,29235.72%
Orland Properties Ltd 15,093,969$52,376,07227.91%
Foresite Capital Management IV, LLC 10,000,000$34,700,00014.82%
MIC Capital Management UK LLP 3,060,569$10,620,1742.10%
Alphabet Inc. 5,865,125$20,351,9841.18%
HSG Holding Ltd 3,045,997$10,569,6101.07%
Artal Group S.A. 700,000$2,4290.14%
Eagle Health Investments LP 100,000$347,0000.08%
Virtus ETF Advisers LLC 39,345$136,5270.07%
BBR PARTNERS, LLC 164,041$569,2220.06%
View complete list of LYELL IMMUNOPHARMA INC shareholders